Symbols / STAB $0.00 +0.00% Statera Biopharma, Inc.

Healthcare • Biotechnology • United States • PNK
STAB Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country PNK · United States
Market Cap 7.14K
Enterprise Value 6.98M
Income -91.83M
Sales 3.69M
FCF (ttm) 340.10K
Book/sh -0.20
Cash/sh 0.01
Employees 46
Insider 10d —
IPO Jul 28, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S 0.00
P/B -0.00
P/C —
EV/EBITDA -0.34
EV/Sales 1.89
Quick Ratio 0.04
Current Ratio 0.06
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -2.36
EPS next Y —
EPS Growth —
Revenue Growth 183.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -23.85%
ROE -286.94%
ROIC —
Gross Margin 70.27%
Oper. Margin -230.65%
Profit Margin 0.00%
Shs Outstand 71.42M
Shs Float 48.11M
Insider Own 0.00%
Instit Own 0.00%
Short Float 1.65%
Short Ratio 0.39
Short Interest 774.53K
52W High 0.03
vs 52W High -99.62%
52W Low 0.00
vs 52W Low 0.00%
Beta 196.47
Impl. Vol. —
Rel Volume 0.12
Avg Volume 6.08K
Volume 700.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$0.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2021-12-31
Total Revenue
0.00
Operating Revenue
0.00
Cost Of Revenue
0.49
Reconciled Cost Of Revenue
0.49
Gross Profit
-0.49
Operating Expense
28.83
Research And Development
11.83
Selling General And Administration
18.49
Selling And Marketing Expense
0.08
General And Administrative Expense
18.41
Salaries And Wages
11.95
Other Gand A
5.82
Other Operating Expenses
-1.49
Total Expenses
29.32
Operating Income
-29.32
Total Operating Income As Reported
-98.34
EBITDA
-29.06
Normalized EBITDA
38.93
Reconciled Depreciation
0.26
EBIT
-29.32
Total Unusual Items
-68.00
Total Unusual Items Excluding Goodwill
-68.00
Special Income Charges
-68.00
Other Special Charges
-1.03
Restructuring And Mergern Acquisition
1.43
Write Off
67.60
Net Income
-101.85
Pretax Income
-101.88
Net Non Operating Interest Income Expense
-4.56
Net Interest Income
-4.56
Other Income Expense
-68.00
Tax Rate For Calcs
0.00
Tax Effect Of Unusual Items
0.00
Net Income Including Noncontrolling Interests
-101.88
Net Income From Continuing Operation Net Minority Interest
-101.85
Net Income From Continuing And Discontinued Operation
-101.85
Net Income Continuous Operations
-101.88
Net Income Discontinuous Operations
0.00
Minority Interests
0.02
Normalized Income
-33.85
Net Income Common Stockholders
-101.85
Diluted EPS
-2.90
Basic EPS
-2.90
Basic Average Shares
35.11
Diluted Average Shares
35.11
Diluted NI Availto Com Stockholders
-101.85
Insurance And Claims
0.64
Total Other Finance Cost
4.56
Line Item Trend 2021-12-31
Total Assets
21.17
Current Assets
4.16
Cash Cash Equivalents And Short Term Investments
1.98
Cash And Cash Equivalents
1.84
Other Short Term Investments
0.13
Receivables
0.35
Accounts Receivable
0.22
Other Receivables
0.13
Prepaid Assets
1.02
Current Deferred Assets
0.61
Restricted Cash
0.17
Assets Held For Sale Current
0.01
Other Current Assets
0.02
Total Non Current Assets
17.01
Net PPE
1.17
Gross PPE
1.20
Accumulated Depreciation
-0.03
Machinery Furniture Equipment
0.20
Other Properties
1.00
Goodwill And Other Intangible Assets
10.85
Goodwill
9.27
Other Intangible Assets
1.58
Other Non Current Assets
5.00
Total Liabilities Net Minority Interest
22.68
Current Liabilities
11.25
Payables And Accrued Expenses
5.72
Payables
3.96
Accounts Payable
3.96
Current Accrued Expenses
1.75
Current Debt And Capital Lease Obligation
4.83
Current Debt
4.58
Other Current Borrowings
4.38
Current Capital Lease Obligation
0.25
Current Deferred Liabilities
0.37
Current Deferred Revenue
0.37
Other Current Liabilities
0.33
Total Non Current Liabilities Net Minority Interest
11.43
Long Term Debt And Capital Lease Obligation
11.43
Long Term Debt
10.62
Long Term Capital Lease Obligation
0.81
Stockholders Equity
-1.57
Common Stock Equity
-1.57
Capital Stock
0.18
Common Stock
0.18
Preferred Stock
0.00
Share Issued
35.48
Ordinary Shares Number
35.48
Additional Paid In Capital
127.74
Retained Earnings
-129.48
Gains Losses Not Affecting Retained Earnings
-0.01
Minority Interest
0.06
Total Equity Gross Minority Interest
-1.51
Total Capitalization
9.06
Working Capital
-7.09
Invested Capital
13.63
Total Debt
16.26
Net Debt
13.36
Capital Lease Obligations
1.06
Net Tangible Assets
-12.42
Tangible Book Value
-12.42
Current Notes Payable
0.20
Interest Payable
0.05
Line Item Trend 2021-12-31
Operating Cash Flow
-28.19
Cash Flow From Continuing Operating Activities
-28.19
Net Income From Continuing Operations
-101.88
Depreciation Amortization Depletion
0.26
Depreciation
0.02
Amortization Cash Flow
0.23
Depreciation And Amortization
0.26
Amortization Of Intangibles
0.23
Other Non Cash Items
-1.30
Stock Based Compensation
6.06
Asset Impairment Charge
67.60
Change In Working Capital
1.07
Change In Receivables
-0.09
Changes In Account Receivables
-0.35
Change In Prepaid Assets
-0.98
Change In Payables And Accrued Expense
1.00
Change In Other Working Capital
0.24
Change In Other Current Assets
0.99
Change In Other Current Liabilities
-0.09
Investing Cash Flow
13.46
Cash Flow From Continuing Investing Activities
13.46
Net PPE Purchase And Sale
-0.18
Purchase Of PPE
-0.18
Capital Expenditure
-0.18
Net Business Purchase And Sale
13.65
Financing Cash Flow
20.99
Cash Flow From Continuing Financing Activities
20.99
Net Issuance Payments Of Debt
13.77
Issuance Of Debt
14.67
Repayment Of Debt
-0.90
Long Term Debt Issuance
14.67
Long Term Debt Payments
-0.90
Net Long Term Debt Issuance
13.77
Net Common Stock Issuance
7.34
Net Other Financing Charges
-0.13
Changes In Cash
6.26
Effect Of Exchange Rate Changes
-0.01
Beginning Cash Position
0.59
End Cash Position
6.84
Free Cash Flow
-28.38
Interest Paid Supplemental Data
1.25
Common Stock Issuance
7.34
Issuance Of Capital Stock
7.34
Net Preferred Stock Issuance
0.00
Preferred Stock Issuance
0.00
Sale Of Business
13.65
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category